top of page
Search

Research Roundup: Oct 31, 2024



Best of cannabinoid science this week...


In humans with PTSD, low doses of THC helped with fear memory processes & extinction learning, both acutely & one week after administration

Dose-dependent effect of acute THC on extinction memory recall and fear renewal: a randomized, double-blind, placebo-controlled study


In people with hand pain, a survey found that the ones using cannabinoids found a similar painkilling effect to prescription medications

Prevalence and Effect of Cannabinoids in Pain Management for Hand Pathologies


In states that legalized medical or recreational cannabis, they had higher levels of physical activity & exercise

Association between cannabis use and physical activity in the United States based on legalization and health status


Finally, someone did a straightforward clinical study of how phytocannabinoids alter the endocannabinoid levels in your blood

Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers

"CBD-led increases in AEA (1.6-fold), OEA and PEA (1.4-fold) were observed following a single 800 mg (pcorr<0.05) but not 600 mg dosage. Declining AEA was observed with Δ9-THC at 10 mg (-1.3-fold) and 20 mg (-1.4-fold) but restored to baseline levels by 160 min. CBD+Δ9-THC yielded the highest increases in AEA (2.1-fold), OEA (1.9-fold) and PEA (1.8-fold) without reaching a maximal response.”


In a related study, in 300 people randomly assigned to products dominant in THC, CBD or both, this research measured the effects on their endocannabinoid levels

The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study

“The findings suggest that AEA levels do not change differently based on 4 weeks of cannabis use or by cannabinoid content, as AEA similarly increased across all conditions from study weeks 2 to 4. In contrast, AEA decreased at an acute administration session with product conditions containing any THC having greater AEA levels on average than the non-use condition. With regard to 2-AG, its levels appeared to primarily be affected by THC-dominant use, both acutely and over 4 weeks, when controlling for baseline cannabis use and examining study product use frequency among use conditions.”


And in another related study, this team measured how cannabis altered immune functions & had anti-inflammatory effects across a range of cell types in the brain

DELTA-9-TETRAHYDROCANNABINOL MODULATES IMMUNOGENOMIC FUNCTION AT SINGLE CELL RESOLUTION USING 10X MULTIOME PROFILING: IN VIVO HUMAN SUBJECT STUDY


In obese people, 8 weeks of 125 mg of oleoylethanolamide (the “anti-hunger” endocannabinoid-like molecule) lowered triglyceride levels

The effect of Oleoylethanolamide supplementation on lipid profile, fasting blood sugar and dietary habits in obese people: a randomized double-blind placebo-control trial


In people exposed to UVA light on their buttocks for two weeks (heroes of science, all of them), two daily topical applications of nano-CBD reduced their redness levels, lowered hyperplasia (abnormally high cell production, a sign of cancer) & protected the skin’s mitochondria (powerhouse of the cell)

Topical Nanoencapsulated Cannabidiol Cream as an Innovative Strategy Combatting Ultraviolet A-Induced Nuclear and Mitochondrial DNA Injury: A Pilot Randomized Clinical Study


A review of the endocannabinoid system as a system of homeostasis (balance)

The Endocannabinoid System Signaling, a Precursor to Homeostasis: A Scoping Review

And a thorough review of cannabis as a food & medicine

Cannabis for medicine and food: A benefit vs risk critical appraisal


For fibromyalgia, a review of 19 publications found improvements to pain, sleep habits & quality of life with no serious adverse events

Effectiveness and safety of cannabis-based products for medical use in patients with fibromyalgia syndrome: A systematic review


For insomnia, a review of six articles found some studies linking medical cannabis with an improvement in sleep quality

The Modulating Role of Cannabis in Insomnia: A Review of the Literature


For migraines, a review of the neural immune cells & the effects of the cannabinoids

Interplay between cannabinoids and the neuroimmune system in migraine


For anxiety, a review of CBD trials that are recent or ongoing

Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol


For neurological disorders, a review of using the cannabinoids

Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders


For depression, a review on targeting the endocannabinoid system

An overview of major depression disorder: The endocannabinoid system as a potential target for therapy


For inflammatory bowel disease, a review on using cannabis

The Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective


In a mouse model of Alzheimer's disease, CBD lowered cognitive decline via glycine receptors in the hippocampus

Cannabidiol ameliorates cognitive decline in 5×FAD mouse model of Alzheimer’s disease through potentiating the function of extrasynaptic glycine receptors


In a rat model of osteoarthritis, the lesser-known cannabinoid cannabiorcol lowered inflammation & osteoarthritis symptoms

Cannabiorcol as a novel inhibitor of the p38/MSK-1/NF-κB signaling pathway, reducing matrix metalloproteinases in osteoarthritis


In honey bees, the anandamide produced by their gut bacteria promoted reward learning

Gut symbiont-derived anandamide promotes reward learning in honeybees by activating the endocannabinoid pathway

Opmerkingen


bottom of page